DRHEA Masterclass in Translational Cancer Research A two day course outlining the principles and practice of modern multidisciplinary translational cancer research. Venue: NICB Seminar Room, Dublin City University Date: Friday 4th & 11th April 2014 Attendance: you must register through http://goo.gl/U2rcR5 or https://www.eventbrite.com/e/masterclass-in-translational-cancerresearch-2-day-course-442014-1142014-tickets-11073815079 or contact [email protected] for further details Attendance is limited and on “a first come first served basis” to those engaged in cancer research. The registration charge for nonDRHEA/ non-ICORG attendees is €350 For students from DRHEA-linked colleges, this course has credit rating of 2.5. Cancer research is making rapid advances through interdisciplinary collaborations between science, medicine and industry. Led by leading researchers from translational cancer research disciplines, this class will give students, scientists, clinicians, nurses and pharma industry representatives an understanding of practice, perspectives and pitfalls in a modern translational cancer research effort. Masterclass in Translational Cancer Research April 4th and 11th 2014, NICB Seminar room, Dublin City University Draft Course Schedule Friday April 4th Date Time 9.00-9.15 9.15-9.30 Title Registration Welcome and Introduction Concept Speaker Welcome and introduction 9.30-10.15 Introduction to Translational Cancer Research Background and challenges in Translational Cancer Research Prof. Martin Clynes, Director – National Institute for Cellular Biotechnology, DCU Dr. Robert O’Connor Senior Programme Leader in Translational Cancer Pharmacology, NICB, DCU. Chair, Translational group, ICORG, 10.15 -10.30 10.30-11.15 Coffee break ICORG – Ireland’s National Clinical Cancer Research Network Ethics committees Operations and research role of ICORG Dr. Fionnuala Keane, Clinical Project Manager, ICORG Translational research considerations from the perspective of the ECs Translational and early stage clinical trial research from the perspective of a hospital pharmacist David Willow, SJH/Tallaght REC 11.15-12.00 12.00-12.45 12.45-1.30 1.30-2.15 Pharmacy and Pharmaceutical Considerations in Translational Research Lunch break The industry perspective on cancer drug development & translational research 2.15-3.00 Clinical Research in Cancer 3-3.15 3.15-4.00 Coffee break Diagnosis Prognosis and Staging of cancer 4.00-4.45 Mutation Analysis in Translational research How Biomarkers Help Patients with Cancer 4.45 – 5.30 Ruth McHugh, Chief II Research Pharmacist, Wellcome trust – HRB Clinical Research Facility, St. James’s Hospital The research realities for cancer Dr. Grainne Power, Head of drug development from an Irish Clinical Operations, RD Projects Pharma Affiliate perspective Clinical Platforms & Sciences – Ireland, GSK Ireland Perspectives on how cancer is Senator, Prof. John Crown, treated and researched Medical Oncologist, SVUH; Director –MTCI/NCRCI How cancer is diagnosed and staged and what material is available for research How to identify mutation in cancer tissue Development and discussion of practicalities cancer biomarkers Dr. Ann Treacy, Consultant Pathologist, Dr. Sinead Toomey, Researcher, Dept of Medical Oncology, RCSI Prof. Joe Duffy, St Vincent's University Hospital and University College, Dublin Friday April 11th Date Time 9.00 -10.15 10.15-10.30 10.15- 11.00 11.00- 11.45 11.45-12.30 12.45 – 1.30 2-2.45 2.45-3.30 3.00-3.15 3.15–4.00 4.00 -4.45 4.45-5 Title Summary of emerging tools & resources relevant to cancer drug development Coffee Break Translational Clinical trial design Translational Protocol development Antibodies in translational cancer research Lunch break Practical issues at the patient Interface Data management in clinical studies Coffee Break Transcriptomic methods in cancer research Proteomic methods in cancer research MCQ –based assessment Concept The modern cancer drug development process Speaker Dr. Robert O’Connor A clinician’s perspective on the rationale and design of translational clinical trials Basic issues developing translational protocols Applications and use of antibodies in cancer research Dr. Ray McDermott, Medical Oncologist, AMNCH and SVUH, ICORG clinical leader Dr. Verena Murphy, Translational Research Manager, ICORG & MTCI Dr. AnneMarie Larkin, Senior Research Scientist - Monoclonal Antibody Research Programme, NICB Translational research from the research nurse perspective Perspectives on generating handling and managing high quality study data Ms. Jo Ballot, Research Nurse Manager, CCRT, SVUH Peter Haughton, Data manager, CCRT, St. Vincent’s University Hospital Applications and procedures in translational cancer transcriptomics Applications and procedures in translational cancer proteomics Dr. Sinead Aherne, Transcriptional Researcher, NICB Compulsory examination for those looking for DRHEA course credit Dr. Paul Dowling, Programme Leader in Clinical Proteomics, NICB Robert O’Connor 5 close Contact Dr. Robert O’Connor on [email protected] for further details on this masterclass. Spaces can be booked using the following website http://goo.gl/U2rcR5 The masterclass will take place in the seminar room of the NICB at Dublin City University, see attached map for directions.